Sarah Langan has a distinguished career in the pharmaceutical and biotechnology sectors, prominently at Eli Lilly and Company since June 2006, where progressions in roles include Sr. Vice President of Synthetic Molecule Development and Associate Vice President overseeing Tides and Analytical Development. With a robust foundation in bioprocess research and development, responsibilities have spanned tech transfer and scale-up of purification processes for GMP clinical trial materials, as well as leading teams in parenteral lyophilization and formulation activities. Prior to Eli Lilly, internships at Dow and Gerber Products Company provided early engineering experience. Sarah Langan holds a Master’s degree in Biomedical/Medical Engineering from Purdue University and a Bachelor’s degree in Chemical Engineering from Rose-Hulman Institute of Technology.
This person is not in any teams
This person is not in any offices